This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0900

Predictive properties of brain-derived neurotrophic factor in rTMS

PREDICTIVE PROPERTIES OF BRAIN DERIVED NEUROTROPHIC FACTOR IN RTMS

Peripheral serum BDNF levels did not predict response to rTMS in major depressive disorder and did not change with rTMS treatment.

The study aimed to investigate the predictive value of peripherally measured serum brain-derived neurotrophic factor (BDNF) in patients receiving repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder (MDD), and whether BDNF was affected by treatment. A post hoc analysis pooled patients receiving routine care and clinical trial participants at the Brain Stimulation Unit of Uppsala University Hospital; a total of 143 individuals were evaluated, comprising clinical patients (n=97, mean age 35, standard deviation (SD) 12, DLPFC target), randomized controlled trial participants (n=38, age 30, SD 10, DMPFC target, iTBS), and an adolescent group (Teen-TMS, n=8, age 16, SD 1). The pooled sample included 64 men and 79 women, with a reported median baseline serum BDNF level of 12.5 ng/mL (interquartile range (IQR) 9.1) and a mean baseline MADRS-S score of 32.6 (SD 7.6). Blood samples were collected from all participants before treatment and only from randomized trial participants after treatment. No significant association was found between baseline serum BDNF levels and changes in MADRS-S scores: r=-0.01 (p=0.903) in clinical patients, r=0.16 (p=0.345) in randomized trial participants, r=-0.07 (p=0.867) in adolescents, and r=-0.02 (p=0.799) across all participants. Active iTBS applied over the DMPFC did not change BDNF concentrations compared with sham iTBS (n=38, F=0.701, p=0.407). The authors concluded that BDNF had no predictive value in rTMS treatment for MDD and did not change as a result of treatment; this finding does not support the use of serum BDNF as a biomarker for patient selection in clinical practice.

All WCP 2026 summaries